Inish O’doherty PhD

Inish O’Doherty, PhD is Executive Director of C-Path’s Type 1 Diabetes (T1D) and Transplant Therapeutic Consortium (TTC). His work focuses on the collaborative selection and development of prognostic biomarkers that can be qualified as Drug Development Tools (DDT) and Novel Methodologies with the FDA and EMA, respectively. Prior to C-Path, Dr. O’Doherty implemented chemical biology target validation methodologies in the drug discovery and development process at Pfizer Inc.